TOR1AIP1

Torsin-1A-interacting protein 1 · Q5JTV8 · TOR1AIP1 on Sugi Atlas →

0 patent compounds predicted against TOR1AIP1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TOR1AIP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Doxycycline In Lymphangioleiomyomatosis (LAM) PHASE4COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome PHASE2WITHDRAWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors PHASE1COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
TECPR2 Observational Study nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma nanCOMPLETED
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans nanUNKNOWN
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
The Role of TBC1D4 in Exercise- and Insulin-induced Glucose Metabolism in Human Skeletal Muscle nanCOMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy nanRECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TOR1AIP1 binder may also engage these)

ProteinNameSimilarity
F1N4E5 1.000 F1N4E5 →
Q5R7A3 1.000 Q5R7A3 →
Q5PQX1 1.000 Q5PQX1 →
Q921T2 1.000 Q921T2 →
Q61029 0.990 Q61029 →
Q8BYU6 0.988 Q8BYU6 →
Q6P752 0.988 Q6P752 →
Q4G0A6 0.988 Q4G0A6 →
P14629 0.987 P14629 →
Q76N89 0.987 Q76N89 →
Q7TP65 0.987 Q7TP65 →
A6QLD2 0.986 A6QLD2 →
Q8K3I4 0.986 Q8K3I4 →
Q5QJC2 0.986 Q5QJC2 →
Q9QYM2 0.985 Q9QYM2 →
Q5RF72 0.985 Q5RF72 →
Q0P557 0.985 Q0P557 →
O35144 0.985 O35144 →
Q8K4P8 0.985 Q8K4P8 →
Q96Q45 0.985 Q96Q45 →
Q3ULM0 0.985 Q3ULM0 →
Q9Y4F4 0.985 Q9Y4F4 →
Q80U16 0.984 Q80U16 →
Q80Y83 0.984 Q80Y83 →
Q6A037 0.984 Q6A037 →
Q9WVR4 0.984 Q9WVR4 →
Q62315 0.984 Q62315 →
Q62733 0.984 Q62733 →
A0JP43 0.984 A0JP43 →
Q9WU61 0.984 Q9WU61 →